Disruption of the Keap1-containing ubiquitination complex as an antioxidant therapy

Current Topics in Medicinal Chemistry

Volumn 7, Issue 10, 2007, Pages 972-978

  Kern, Jonathan T ^a   Hannink, Mark ^b   Hess, J Fred ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b University of Missouri   (United States)

Author keywords

Antioxidant; Antioxidant response element; Cul3; Keap1; Nrf2; Oxidative stress

Indexed keywords

1 BIOTINAMIDO 4 [4' (MALEIMIDOETHYLCYCLOHEXANE)CARBOXAMIDO]BUTANE; ADAPTOR PROTEIN; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; BROCCOLI EXTRACT; EPIGALLOCATECHIN GALLATE; FERRITIN; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; HL 198C; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MI 17; N IODOACETYL N BIOTINYLHEXYLENEDIAMINE; NUTLIN 1; OXINDOLE; PHENYL ISOTHIOCYANATE; PLANT EXTRACT; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SULFORAPHANE; TERT BUTYL HYDROQUINONE; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; BROCCOLI; CANCER; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COMPLEX FORMATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIMARY PREVENTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TARDIVE DYSKINESIA; TRANSACTIVATION; UBIQUITINATION; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RESPONSE ELEMENTS; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 34447258909     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780906825     Document Type: Review

References (62)

1. Klebanoff, S.J. Myeloperoxidase: friend and foe. J. Leukoc. Biol., 2005, 77, 598-625.
2. Lanza, F. Clinical manifestation of myeloperoxidase deficiency. J. Mol. Med., 1999, 76, 676-681.
3. Terada, L.S. Specificity in reactive oxidant signaling: think globally, act locally. J. Cell Biol., 2006, 174, 615-623.
4. Pham, D.Q.; Plakogiannis, R. Vitamin E supplementation in cardiovascular disease and cancer prevention: Part 1. Ann. Pharmacother., 2005, 39, 1870-1878.
5. Pham, D.Q.; Plakogiannis, R. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. Ann. Pharmacother., 2005, 39, 2065-2072.
6. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med., 1999, 330, 1029-1035.
7. Hercberg, S.; Galan, P.; Preziosi, P.; Bertrais, S.; Mennen, L.; Malvy, D.; Roussel, A.M.; Favier, A.; Briancon, S. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch. Intern. Med., 2004, 164, 2335-2342.
8. Galan, P.; Briancon, S.; Favier, A.; Bertrais, S.; Preziosi, P.; Faure, H.; Arnaud, J.; Arnault, N.; Czernichow, S.; Mennen, L.; Hercberg, S. Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels?. Br. J. Nutr., 2005, 94, 125-132.
9. Rushmore, T.H.; Morton, M.R.; Pickett, C.B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem., 1991, 266, 11632-11639.
10. Itoh, K.; Igarashi, K.; Hayashi, N.; Nishizawa, M.; Yamamoto, M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell Biol., 1995, 15, 4184-4193.
11. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; Yamamoto, M.; Nabeshima, Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., 1997, 236, 313-322.
12. Moi, P.; Chan, K.; Asunis, I.; Cao, A.; Kan, Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandern NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA, 1994, 91, 9926-9930.
13. Hu, R.; Xu, C.; Shen, G.; Jain, M.R.; Khor, T.O.; Gopalkrishnan, A.; Lin, W.; Reddy, B.; Chan, J.Y.; Kong, A.N. Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci., 2006, 79, 1944-1955.
14. Hu, R.; Xu, C.; Shen, G.; Jain, M.R.; Khor, T.O.; Gopalkrishnan, A.; Lin, W.; Reddy, B.; Chan, J.Y.; Kong, A.N. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett., 2006, 243, 170-192.
15. Thimmulappa, R.K.; Mai, K.H.; Srisuma, S.; Kensler, T.W.; Yamamoto, M.; Biswal, S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res., 2002, 62, 5196-5203.
16. Shen, G.; Xu, C.; Hu, R.; Jain, M.R.; Nair, S.; Lin, W.; Yang, C.S.; Chan, J.Y.; Kong, A.N. Comparison of (-)-epigallocatechin-3-gallate, elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm. Res., 2005, 22, 1805-1820.
17. Kwak, M.K.; Wakabayashi, N.; Itoh, K.; Motohashi, H.; Yamamoto, M.; Kensler, T.W. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem., 2003, 278, 8135-8145.
18. Dinkova-Kostova, A.T.; Holtzclaw, W.D.; Cole, R.N.; Itoh, K.; Wakabayashi, N.; Katoh, Y.; Yamamoto, M.; Talalay, P. Direct evidence that sulfhydryl groups of Keap1 arc the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. USA, 2002, 99, 11908-11913.
19. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel, J.D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev., 1999, 13, 76-86.
20. McMahon, M.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem., 2003, 278, 21592-21600.
21. Zhang, D.D.; Hannink, M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell Biol., 2003, 23, 8137-8151.
22. Devling, T.W.; Lindsay, C.D.; McLellan, L.I.; McMahon, M.; Hayes, J.D. Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc. Natl. Acad. Sci. USA, 2005, 102, 7280-7285.
23. Wakabayashi, N.; Itoh, K.; Wakabayashi, J.; Motohashi, H.; Noda, S.; Takahashi, S.; Imakado, S.; Kotsuji, T.; Otsuka, F.; Roop, D.R.; Harada, T.; Engel, J.D.; Yamamoto, M. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet., 2003, 35, 238-245.
24. Stogios, P.J.; Prive, G.G. The BACK domain in BTB-kelch proteins. Trends Biochem. Sci., 2004, 29, 634-637.
25. Zipper, L.M.; Mulcahy, R.T. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J. Biol. Chem., 2002, 277, 36544-36552.
26. Furukawa, M.; Xiong, Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Rocl ligase. Mol. Cell Biol., 2005, 25, 162-171.
27. Kobayashi, A.; Kang, M.I.; Okawa, H.; Ohtsuji, M.; Zenke, Y.; Chiba, T.; Igarashi, K.; Yamamoto, M. Oxidative stress sensor Keap1 functions as an adaptor for Cu13-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell Biol., 2004, 24, 7130-7139.
28. Zhang, D.D.; Lo, S.C.; Cross, J.V.; Templeton, D.J.; Hannink, M. Keap1 is a redox-regulated substrate adaptor protein for a Cu13-dependent ubiquitin ligase complex. Mol. Cell Biol., 2004, 24, 10941-10953.
29. Cullinan, S.B.; Gordan, J.D.; Jin, J.; Harper, J.W.; Diehl, J.A. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cu13-bascd E3 ligase: oxidative stress sensing by a Cu13-Keap1 ligase. Mol. Cell Biol., 2004, 24, 8477-8486.
30. Petroski, M.D.; Deshaies, R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol., 2005, 6, 9-20.
31. Lo, S.C.; Hannink, M. CAND1-mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1. Mol. Cell Biol., 2006, 26, 1235-1244.
32. Dinkova-Kostova, A.T.; Massiah, M.A.; Bozak, R.E.; Hicks, R.J.; Talalay, P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. USA, 2001, 98, 3404-3409.
33. Hong, F.; Sekhar, K.R.; Freeman, M.L.; Liebler, D.C. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J. Biol. Chem., 2005, 280, 31768-31775.
34. Zhang, D.D.; Lo, S.C.; Sun, Z.; Habib, G.M.; Lieberman, M.W.; Hannink, M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cu13, targets Keap1 for degradation by a proteasome-independent pathway. J. Biol. Chem., 2005, 280, 30091-30099.
35. Zheng, N.; Schulman, B.A.; Song, L.; Miller, J.J.; Jeffrey, P.D.; Wang, P.; Chu, C.; Koepp, D.M.; Elledge, S.J.; Pagano, M.; Conaway, R.C.; Conaway, J.W.; Harper, J.W.; Pavletich, N.P. Structure of the Cull-Rbx1-Skpl-F boxSkp2 SCF ubiquitin ligase complex. Nature, 2002, 416, 703-709.
36. Satoh, T.; Okamoto, S.I.; Cui, J.; Watanabe, Y.; Furuta, K.; Suzuki, M.; Tohyama, K.; Lipton, S.A. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc. Natl. Acad. Sci. USA, 2006, 103, 768-773.
37. Sakurai, T.; Kanayama, M.; Shibata, T.; Itoh, K.; Kobayashi, A.; Yamamoto, M.; Uchida, K. Ebselen, a seleno-organic antioxidant, as an electrophile. Chem. Res. Toxicol., 2006, 19, 1196-1204.
38. Eggler, A.L.; Liu, G.; Pezzuto, J.M.; van Breemen, R.B.; Mesecar, A.D. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl. Acad. Sci. USA, 2005, 102, 10070-10075.
39. Allen, E.; Ding, J.; Wang, W.; Pramanik, S.; Chou, J.; Yau, V.; Yang, Y. Gigaxonin controlled degradation of MAP1B light chain is critical to neuronal survival. Nature, 2005, 438, 224-228.
40. Li, X.; Zhang, D.; Hannink, M.; Beamer, L.J. Crystal structure of the Kelch domain of human Keap1. J. Biol. Chem., 2004, 279, 54750-54758.
41. Lo, S.C.; Li, X.; Henzl, M.T.; Beamer, L.J.; Hannink, M. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J., 2006, 25, 3605-3617.
42. Padmanabhan, B.; Tong, K.I.; Ohta, T.; Nakamura, Y.; Scharlock, M.; Ohtsuji, M.; Kang, M.I.; Kobayashi, A.; Yokoyama, S.; Yamamoto, M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer, Mol. Cell, 2006, 21, 689-700.
43. Tong, K.I.; Katoh, Y.; Kusunoki, H.; Itoh, K.; Tanaka, T.; Yamamoto, M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell Biol., 2006, 26, 2887-2900.
44. McMahon, M.; Thomas, N.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem., 2006, 281, 24756-24768.
45. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303, 844-848.
46. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y.; Gan, W.; Stuckey, J.; Krajewski, K.; Roller, P.P.; Tomita, Y.; Parrish, D.A.; Deschamps, J.R.; Wang, S. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc., 2005, 127, 10130-10131.
47. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P.P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molocule inhibitors of the MDM2-p53 interaction. J. Med. Chem., 2006, 49, 3432-3435.
48. Yang, Y.; Ludwig, R.L.; Jensen, J.P.; Pierre, S.A.; Medaglia, M.V.; Davydov, I.V.; Safiran, Y.J.; Oberoi, P.; Kenten, J.H.; Phillips, A.C.; Weissman, A.M.; Vousden, K.H. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell, 2005, 7, 547-559.
49. Issaeva, N.; Bozko, P.; Enge, M.; Protopopova, M.; Verhoef, L.G.; Masucci, M.; Pramanik A.; Selivanova, G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med., 2004, 10, 1321-1328.
50. Banks, D.; Wu, M.; Higa, L.A.; Gavrilova, N.; Quan, J.; Ye, T.; Kobayashi, R.; Sun, H.; Zhang, H. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle, 2006, 5, 1719-1729.
51. Iida, K.; Itoh, K.; Kumagai, Y.; Oyasu, R.; Hattori, K.; Kawai, K.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res., 2004, 64, 6424-6431.
52. Ramos-Gomez, M.; Kwak, M.K.; Dolan, P.M.; Itoh, K.; Yamamoto, M.; Talalay, P.; Kensler, T.W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA, 2001, 98, 3410-3415.
53. Xu, C.; Huang, M.T.; Shen, G.; Yuan, X.; Lin, W.; Khor, T.O.; Conney, A.H.; Tony Kong, A.N. Inhibition of 7,12-Dimethylbenz(a)anthracene-Induced Skin Tumorigenesis in C57BL/6 Mice by Sulforaphane Is Mediated by Nuclear Factor E2-Related Factor 2. Cancer Res., 2006, 66, 8293-8296.
54. Yates, M.S.; Kwak, M.K.; Egner, P.A.; Groopman, J.D.; Bodreddigari, S.; Sutter, T.R.; Baumgartner, K.J.; Roebuck, B.D.; Liby, K.T.; Yore, M.M.; Honda, T.; Gribble, G.W.; Sporn, M.B.; Kensler, T.W. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid. 1-[2-cyano-3-,12-dioxooleana- 1,9(11)-dien-28-oyl]imidazole. Cancer Res., 2006, 66, 2488-2494.
55. Shih, A.Y.; Imbeault, S.; Barakauskas, V.; Erb, H.; Jiang, L.; Li, P.; Murphy, T.H. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem., 2005, 280, 22925-22936.
56. Burton, N.C.; Kensler, T.W.; Guilarte, T.R. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology, 2006, 27(6), 1094-100.
57. Shih, A.Y.; Li, P.; Murphy, T.H. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J. Neurosci., 2005, 25, 10321-10335.
58. Zhao, J.; Kobori, N.; Aronowski, J.; Dash, P.K. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci. Lett., 2006, 393, 108-112.
59. Ishii, Y.; Itoh, K.; Morishima, Y.; Kimura, T.; Kiwamoto, T.; Iizuka, T.; Hegab, A.E.; Hosoya, T.; Nomura, A.; Sakamoto, T.; Yamamoto, M.; Sekizawa, K. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J. Immunol., 2005, 175, 6968-6975.
60. Evans, D.C.; Watt, A.P.; Nicoll-Griffith, D.A.; Baillie, T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 2004, 17, 3-16.
61. Evans, D.C.; Baillie, T.A. Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug Discov. Devel., 2005, 8, 44-50.
62. Shapiro, T.A.; Fahey, J.W.; Dinkova-Kostova, A.T.; Holtzclaw, W.D.; Stephenson, K.K.; Wade, K.L.; Ye, L.; Talalay, P. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr. Cancer, 2006, 55, 53-62.